Abstract
Within the last decades significant progress has been made in the understanding of the underlying pathophysiological mechanisms of migraine. There is a general agreement now that migraine is not only a vascular phenomenon but also a genetically determined heterogenic ion-channelopathy resulting in cortical-spreading-depression-like events, the temporary impairment of antinociceptive structures of the brainstem and the activation of the trigeminal-vascular system. The development and use of drugs targeting ion-channels and subsequently reducing cortical excitability appears as a promising avenue for both the acute treatment of migraine and migraine prevention. This review summarizes the current knowledge and evidence for GABAergic drugs in the treatment of migraine.
Keywords: GABA transaminase, Topiramate, Valproic acid, Gabapentin, pregabalin
CNS & Neurological Disorders - Drug Targets
Title: GABAergic Drugs for the Treatment of Migraine
Volume: 6 Issue: 4
Author(s): Anja Puppe and Volker Limmroth
Affiliation:
Keywords: GABA transaminase, Topiramate, Valproic acid, Gabapentin, pregabalin
Abstract: Within the last decades significant progress has been made in the understanding of the underlying pathophysiological mechanisms of migraine. There is a general agreement now that migraine is not only a vascular phenomenon but also a genetically determined heterogenic ion-channelopathy resulting in cortical-spreading-depression-like events, the temporary impairment of antinociceptive structures of the brainstem and the activation of the trigeminal-vascular system. The development and use of drugs targeting ion-channels and subsequently reducing cortical excitability appears as a promising avenue for both the acute treatment of migraine and migraine prevention. This review summarizes the current knowledge and evidence for GABAergic drugs in the treatment of migraine.
Export Options
About this article
Cite this article as:
Anja Puppe and Volker Limmroth , GABAergic Drugs for the Treatment of Migraine, CNS & Neurological Disorders - Drug Targets 2007; 6 (4) . https://dx.doi.org/10.2174/187152707781387305
DOI https://dx.doi.org/10.2174/187152707781387305 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sub-Chronic Exposure of Non-Observable Adverse Effect Dose of Terbufos Sulfone: Neuroinflammation in Diabetic and Non-Diabetic Rats
CNS & Neurological Disorders - Drug Targets Neuropeptide Y as an Endogenous Antiepileptic, Neuroprotective and Pro-Neurogenic Peptide
Recent Patents on CNS Drug Discovery (Discontinued) Patent Selections:
Recent Patents on Biomedical Engineering (Discontinued) Mevalonate Cascade and Neurodevelopmental and Neurodegenerative Diseases: Future Targets for Therapeutic Application
Current Molecular Pharmacology Neurological Disorders in Medical Use of <i>Cannabis</i>: An Update
CNS & Neurological Disorders - Drug Targets Dysfunction of Mitochondrial ATP Production As a Target for Personalized Cancer Therapy
Current Pharmacogenomics and Personalized Medicine Role of Oxidative Stress in Polycystic Ovary Syndrome
Current Women`s Health Reviews Extracellular Vesicles in Glioblastoma: Role in Biological Processes and in Therapeutic Applications
Current Cancer Drug Targets Oxidative Stress in Traumatic Brain Injury
Current Medicinal Chemistry Screening the Receptorome Yields Validated Molecular Targets for Drug Discovery
Current Pharmaceutical Design n-3 Fatty Acids: Role in Neurogenesis and Neuroplasticity
Current Medicinal Chemistry Editorial [Hot topic: Chemical Agents Positively and Negatively Affecting the Central Nervous System (Guest Editors: Abel Santamaria & Mauricio Diaz-Munoz)]
Central Nervous System Agents in Medicinal Chemistry Examination of Hippocampal Differences Between Alzheimer Disease, Amnestic Mild Cognitive Impairment and Normal Aging: Diffusion Kurtosis
Current Alzheimer Research Chvostek's Sign in Paediatric Practice
Current Pediatric Reviews Conotoxins-New Vistas for Peptide Therapeutics
Current Pharmaceutical Design Synthesis and Analysis of Anticonvulsant Activities of New 4-[2-(4- alkoxybenzylamino)ethyl]-2H-1,2,4-triazol-3(4H)-one Derivatives
Letters in Drug Design & Discovery The Role of Adenosine in Alzheimers Disease
Current Neuropharmacology Anticonvulsant Sulfonamides/Sulfamates/Sulfamides with Carbonic Anhydrase Inhibitory Activity: Drug Design and Mechanism of Action
Current Pharmaceutical Design Adult Neurogenesis: Can Analysis of Cell Cycle Proteins Move Us “Beyond BrdU”?
Current Pharmaceutical Biotechnology Pharmacotherapy and the Psychobiological Model of Personality: Implications for DSM-5
Current Psychopharmacology